The PurpleLab^® Resource Center

This study was run to determine if a racial disparity exists in biomarker testing for NSCLC (non-small cell lung cancer) patients. Jared Safran, PharmD, MS, Russell Robbins, MD, MBA, Maggie Mendes, Douglas Londono, PhD, Grace Kane, MS. Healthcare is evolving into precision medicine or what the FDA refers to as personalized medicine1. This targeted approach…

PurpleLab’s® Clinical Trial data provides detailed metrics on clinical trial activities performed by healthcare providers (HCPs) and healthcare organizations (HCOs). By integrating clinical trial data, overall profiles of HCPs and HCOs are enhanced, offering a clearer view of a provider’s clinical research experience. With this added visibility, users can efficiently segment and identify potential investigators and…

This study was run to evaluate whether provider specialty is a driver for biosimilar adoption, defined as adoption probability difference (APD). Diane Faraone, PharmD, Russell Robbins, MD, MBA, Grace Kane, MS, Douglas Londono, PhD.  The US biologics market has significantly expanded in recent years; projected to reach $62 billion in prescription drug spend by 2025. Biosimilar…